Table 2.
Clinical characteristics at baseline (n = 331)
| Characteristic | Value |
|---|---|
| Age, mean (s.d.), years | 50.7 (13) |
| Male, n (%) | 171 (52) |
| Symptom duration, median (IQR), years | 0.9 (0.3–2.8) |
| Swollen joint count (66), median (IQR) | 2 (1–4) |
| Tender joint count (68), median (IQR) | 3 (1–7) |
| LEI > 0, n (%) | 130 (39) |
| LEI if positive, median (IQR) | 2 (1–3) |
| LDI > 0, n (%) | 50 (15) |
| PASI, median (IQR) | 2 (0.5–4.0) |
| VAS Global, mean (s.d.) | 46 (26) |
| VAS Pain, mean (s.d.) | 46 (26) |
| HAQ, median (IQR) | 0.6 (0.4–1.0) |
| DAS28, mean (s.d.) | 3.1 (1.1) |
| DAPSA, mean (s.d.) | 18 (11) |
| CPDAI, mean (s.d.) | 3.9 (1.9) |
| PASDAS, mean (s.d.) | 4.1 (1.2) |
| GRACE, mean (s.d.) | 3.4 (1.5) |
| MDA, mean (s.d.) | 51 (15) |
CPDAI: Composite Psoriatic Disease Activity Index; DAPSA: Disease Activity index for PSoriatic Arthritis; DAS28: Disease Activity Score 28; GRACE: GRAppa Composite ScorE; IQR: interquartile range; LEI: Leeds Enthesitis Index; LDI: Leeds Dactylitis Index; MDA: Minimal Disease Activity; PASDAS: Psoriatic ArthritiS Disease Activity Score; PASI: Psoriasis Area and Severity Index; VAS: visual analogue scale.